Sudeep Pharma Limited Announces Financial Results and Recommends Final Dividend for FY 2026
Sudeep Pharma Limited announced significant corporate decisions following its Board of Directors meeting held on May 21, 2026. The Board considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.The Board also recommended a Final Dividend of Rs. 1.50 per equity share, representing 150% of the face value of Rs. 1 per share, for the financial year ended March 31, 2026, subject to the approval of shareholders at the upcoming Annual General Meeting.
Financial Performance Summary
The company presented its consolidated financial results for the year ended March 31, 2026. The consolidated results show key performance metrics in both the standalone and consolidated formats.The financial metrics for the year ended March 31, 2026, are detailed below:
| Metric | For the Year Ended 31 March 2026 (Audited) | For the Year Ended 31 March 2025 (Audited) |
|---|---|---|
| Total Income | 67,084.34 Lakhs | 51,132.83 Lakhs |
| Total Expenses | 44,276.90 Lakhs | 32,848.32 Lakhs |
| Profit before Tax | 22,807.44 Lakhs | 18,284.51 Lakhs |
| Total Tax Expenses | 5,378.97 Lakhs | 2,411.59 Lakhs |
| Profit for the Period (Attributable to Owners of the Group) | 17,428.47 Lakhs | 13,872.92 Lakhs |
| Total Comprehensive Income for the Period | 17,305.95 Lakhs | 13,709.41 Lakhs |
Segment Revenue Overview
In terms of segment performance, the consolidated revenue generated was Rs. 64,225.80 lakhs for the year ended March 31, 2026, compared to Rs. 50,199.92 lakhs in the previous year.| Segment | Year Ended 31 March 2026 Revenue ( Lakhs) | Year Ended 31 March 2025 Revenue ( Lakhs) |
|---|---|---|
| Pharmaceutical, food and nutrition | 36,263.91 | 33,049.62 |
| Speciality ingredients | 17,150.30 | 17,150.30 |
| Total Revenue from Operations | 53,414.21 | 50,199.92 |
Governance and Statutory Appointments
The Board meeting also formalized the appointment of statutory auditors for the upcoming financial years.The following professional firms were approved for appointment:
- Cost Auditor: M/s. Chetan Gandhi & Associates, Cost Accountants, were approved as the Cost Auditor for the Financial Year 2026-27.
- Secretarial Auditor: M/s. H M Mehta & Associates, Company Secretaries, were approved as the Secretarial Auditor for a consecutive period of five years, covering the Financial Years 2026-27 through 2030-31.
Financial Position (Balance Sheet Snapshot)
The company’s consolidated Balance Sheet as at March 31, 2026, reported the following assets and liabilities:| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| Total Non-Current Assets | 41,930 Lakhs | N/A |
| Total Current Assets | 6,014.88 Lakhs | 4,798.81 Lakhs |
| TOTAL ASSETS | 51,582.61 Lakhs | 29,107.59 Lakhs |
| Total Equity | 75,600.92 Lakhs | 30,119.10 Lakhs |
| Total Liabilities | 18,769.26 Lakhs | 17,397.60 Lakhs |
Note: Figures are reported in Lakhs.
Cash Flow Highlights
The consolidated Statement of Cash Flows indicates a significant cash generation through operations.| Activity | Year Ended 31 March 2026 (Audited) | Year Ended 31 March 2025 (Audited) |
|---|---|---|
| Net cash generated from operating activities | 6,955.29 Lakhs | 4,872.68 Lakhs |
| Net cash used in Investing activities | (33,092.98) Lakhs | (7,875.56) Lakhs |
| Net cash generated from Financing activities | 24,728.75 Lakhs | 5,269.61 Lakhs |
| Net increase in cash and cash equivalents | (1,408.9) Lakhs | 2,266.73 Lakhs |
The Board's decisions mark the completion of the annual financial reporting cycle, providing transparency into the company's operational scope and financial stability for the period ending March 31, 2026.
SUDEEPPHRM Stock Price Movement
Today, Sudeep Pharma Limited shares edged higher, settling at ₹668.2 after gaining ₹14.90, representing a 2.29% increase. The equity finished the day robustly, trading on a volume of 118,876 shares after marking a range between ₹656 and ₹680.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: